Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death
- PMID: 15306095
- DOI: 10.1007/s11886-004-0041-8
Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death
Abstract
Torsades de pointes (TdP) is a potentially life-threatening arrhythmia associated with not only antiarrhythmic drugs, but noncardiac drugs of many different classes. All these drugs prolong the QT interval by their blocking of the potassium channel I(Kr), and many are metabolized by the cytochrome P450 isoenzyme CYP3A4. Polypharmacy with other drugs utilizing the same enzyme, or inhibiting CYP3A4, can lead to TdP. A consistent finding of all the QT-prolonging drugs is predominance of TdP in women. Other risk factors for QT prolongation and TdP include hypokalemia, congestive heart failure, and structural heart disease. Knowledge of potential drug interactions and other risk factors for TdP can help in reducing the number of adverse events associated with the use of QT-prolonging drugs.
Similar articles
-
Drug-induced QT prolongation and sudden death.Mo Med. 2010 Jan-Feb;107(1):53-8. Mo Med. 2010. PMID: 20222297 Free PMC article. Review.
-
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.Drugs. 2002;62(11):1649-71. doi: 10.2165/00003495-200262110-00006. Drugs. 2002. PMID: 12109926 Review.
-
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.Cardiovasc Res. 2003 Apr 1;58(1):32-45. doi: 10.1016/s0008-6363(02)00846-5. Cardiovasc Res. 2003. PMID: 12667944 Review.
-
[QTc-prolonging drugs and the risk of sudden death].Medicina (Kaunas). 2007;43(4):347-53. Medicina (Kaunas). 2007. PMID: 17485963 Review. Lithuanian.
-
Pharmacologic agents associated with QT interval prolongation.J Fam Pract. 2005 Jun;Suppl:S8-S14. J Fam Pract. 2005. PMID: 15938993 Review.
Cited by
-
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.Br J Haematol. 2011 Sep;154(5):579-89. doi: 10.1111/j.1365-2141.2011.08786.x. Epub 2011 Jun 28. Br J Haematol. 2011. PMID: 21707585 Free PMC article. Clinical Trial.
-
HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease.Cells. 2025 Jul 20;14(14):1116. doi: 10.3390/cells14141116. Cells. 2025. PMID: 40710369 Free PMC article. Review.
-
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.Support Care Cancer. 2016 Feb;24(2):621-627. doi: 10.1007/s00520-015-2822-6. Epub 2015 Jun 26. Support Care Cancer. 2016. PMID: 26111957 Free PMC article. Clinical Trial.
-
Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions.Br J Clin Pharmacol. 2013 Dec;76(6):964-72. doi: 10.1111/bcp.12151. Br J Clin Pharmacol. 2013. PMID: 23617533 Free PMC article. Clinical Trial.
-
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3. Future Med Chem. 2012. PMID: 22416777 Free PMC article. Review.